WP5 JA1 Pilot Pazopanib Report+Appendix
WP5 JA1 Pilot Pazopanib Report+Appendix The final version of the WP5 JA1 pilot assessment using the draft model for Rapid Relative Effectiveness Assessment of Pharmaceuticals and guidelines. The joint assessment involved the participation of 22 HTA organisations as authors on different domains or as reviewers. Find the full list on page 16 in side the report. The […]
Summary report of the SF e-meeting, 17 September 2013
This document is the summary report of the Stakeholder Forum e-meeting, 17 September, 2013. It presents key discussion and actions points decided at this meeting. Agenda A. General information and updates Overview of action points (last e-meeting) and their status (written status overview in the background documents) JA2 WP updates (including JA2 SAG activities update) EUnetHTA Expert meetings […]
EUnetHTA Joint Action 2 3-year Work plan (2013)
The EUnetHTA Joint Action 2 3-Year Work Plan lays out details and timelines of the activities planned in each of the eight Work Packages of EUnetHTA JA2 and guides the work of EUnetHTA throughout 2012-2015. The EUnetHTA Executive Committee monitors the implementation of the Work Plan and discusses if any prospective amendments need to be […]
WP5 Strand B – Procedure Manual V3
This document describes processes planned for conducting pilot rapid assessments for other technologies such as medical devices, surgical interventions or diagnostics. Since the Procedure Manual is a living document, further changes can be expected due to experiences gathered throughout JA2. Procedure Manual V3.pdf
EUnetHTA’s joint response to the public consultation on PAES_Amendments from IQWiG to HAS comments
Amendments_IQWiG_To_HAS_PAES joint response.pdf
Prognostic tests for breast cancer recurrence (PTBCR)
The three tests assessed in this core health technology assessment (HTA)— uPA/PAI-1 (FEMTELLE®, American Diagnostica) based on immunostaining techniques and MammaPrint® (Agendia) and Oncotype DX® (Genomic Health), based on gene expression profiling—measure multiple markers within the tumour that may indicate how the tumour is likely to develop. Agenas, Italy and SNHTA, Switzerland are the editors […]
WP5 Products
It is the remit of WP5 to develop tools for relative effectiveness assessment of pharmaceuticals. This document briefly presents the products of WP5 from EUnetHTA Joint Action 1. It is the remit of WP5 to develop tools for relative effectiveness assessment of pharmaceuticals. This document briefly presents the products of WP5 from EUnetHTA Joint Action […]
External Initiatives Management Policy
This is the policy on the management of EUnetHTA’s involvement in external initiatives. EUnetHTA’s involvement in external initiatives_Policy
Presentations 1-13 from the EMA-EUnetHTA meeting, 20 November 2012
These are all 13 presentations from the EMA-EUnetHTA meeting 20 November 2012. They are listed in the order as they are presented in the Summary report. Presentations 1-13 from the EMA-EUnetHTA meeting, 20 November 2012
EUnetHTA Strategy 2012 and beyond
This document presents the EUnetHTA Strategy 2012 and beyond. Common interests and policies in relation to HTA have been explored and developed at the strategic level in the European Union for ten years. EUnetHTA (European network for HTA) has been a major platform for supporting this process, since its inception in 2006. Operating currently through […]
